2020-06-15
It is with great pleasure to welcome Pål Falck as a CBO for Oncorena, starting September 1, 2020. Pål brings a breadth of relevant experience and competence to strengthen our leadership in time for the exciting next development steps of Oncorena.
Pål joins us from Arctic Securities AS, Oslo where is was en Equity Research Analyst covering Healthcare. Before that he has been with Pfizer and AstraZeneca in medical assignments, including Medical Director and Scout for external opportunities, covering Oncology and other therapeutic areas.
Pål is trained as a pharmacist from University of Oslo and he has a Ph.D. in an area of great relevance to Oncorena, – pharmacokinetics and renal transplantation. He has also a degree as Executive Master of Management. BI, from Norwegian Business School.
Please, join me in congratulating Pål to his new appointment!
Lars Grundemar, M.D., Ph.D.
Chief Executive Officer
Oncorena AB
2021-03-01
Oncorena, dedicated to developing a unique and potential breakthrough therapy for metastatic renal cancer,…
Read more2020-06-15
It is with great pleasure to welcome Pål Falck as a CBO for Oncorena, starting September 1, 2020. Pål brin…
Read more2018-11-22
Oncorena Holding AB today announces that the company through a share issue has raised capital to build its…
Read more